SCHEMBL1205124

SCHEMBL1205124

CC(C)(C)OC(=O)C(N)c1ccc(C(=O)O)c(C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.61
TDP1 Q9NUW8 6/20 0.61
KMT2A Q03164 4/20 0.61
MEN1 O00255 3/20 0.61
CYP2C9 P11712 3/20 0.61
CYP2C19 P33261 2/20 0.61
CYP2D6 P10635 1/20 0.61
GRM8 O00222 1/20 0.61
GRM6 O15303 1/20 0.61
SLC6A2 P23975 1/20 0.61
SLC6A4 P31645 1/20 0.61
DRD3 P35462 1/20 0.61
GRM4 Q14833 1/20 0.61
ALDH1A1 P00352 6/20 0.46
GRM1 Q13255 5/20 0.46
KDM4E B2RXH2 4/20 0.46
HPGD P15428 4/20 0.46
GRM2 Q14416 2/20 0.46
EDNRA P25101 1/20 0.36
APP P05067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651392 0.88 TDP1 (0.46) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL3657503 0.88 HSD17B10 (0.46) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL27878879 0.87 HSD17B10 (0.45) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL1018438 0.87 HSD17B10 (0.45) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL27472748 0.87 HSD17B10 (0.45) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL27821924 0.83 DTYMK (0.45) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL27801149 0.83 HSD17B10 (0.41) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL27801161 0.81 HSD17B10 (0.40) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL27821926 0.80 HSD17B10 (0.39) HSD17B10TDP1KMT2AMEN1CYP2C9
SCHEMBL506934 0.80 ANPEP (0.45) TDP1KMT2AMEN1ALDH1A1GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1724263-B1 BASIC AMINE COMPOUND AND USE THEREOF KUREHA CORP (JP) 2014-03-05 EP disclosed
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US disclosed
US-7932281-B2 Amine-based compound and use thereof KUREHA CORPORATION (JP) 2011-04-26 US disclosed
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-02-24 US disclosed
US-7833991-B2 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2010-11-16 US disclosed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US disclosed
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2007-09-06 US disclosed
US-7176227-B2 For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis KUREHA CORPORATION (JP) 2007-02-13 US disclosed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP disclosed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US disclosed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF NR0B2, NR5A2, NR1D2 HSD17B10 608/4885TDP1 3917/4885KMT2A 474/4885
US-20050165063-A1 Amine compounds and use thereof NR0B2, NR5A2, NR1H4 HSD17B10 423/4885TDP1 4143/4885KMT2A 721/4885
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF NR0B2, NR1D2, NR0B1 HSD17B10 505/4885TDP1 4336/4885KMT2A 559/4885
US-20070208007-A1 Amine-Based Compound and Use Thereof NR0B2, NR5A2, NR2E1 HSD17B10 480/4885TDP1 3702/4885KMT2A 488/4885
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists CXCR4, CXCR6, CCR5 HSD17B10 1898/4885TDP1 4598/4885KMT2A 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.